OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Showing 9 citing articles:
Potential benefits and possible risks of CGRP-targeted multitherapy in migraine
Keiko Ihara, Tsubasa Takizawa, Narumi Watanabe, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 1-2, pp. 1-4
Open Access | Times Cited: 4
Keiko Ihara, Tsubasa Takizawa, Narumi Watanabe, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 1-2, pp. 1-4
Open Access | Times Cited: 4
Headache Assessment Via Digital Platform in United States (HeAD-US): Baseline Study Characteristics, Diagnosis, and Treatment Patterns
Ali Ezzati, Kristina M. Fanning, Devin Teichrow, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Ali Ezzati, Kristina M. Fanning, Devin Teichrow, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine
Dilara Onan, Fatemeh Farham, Paolo Martelletti
Toxins (2024) Vol. 16, Iss. 7, pp. 309-309
Open Access | Times Cited: 3
Dilara Onan, Fatemeh Farham, Paolo Martelletti
Toxins (2024) Vol. 16, Iss. 7, pp. 309-309
Open Access | Times Cited: 3
Combining treatments for migraine prophylaxis: the state-of-the-art
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Lanfranco Pellesi, David García‐Azorín, Eloísa Rubio‐Beltrán, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients
Yang Zhao, Xiaodan Wang, Mengyue Niu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Yang Zhao, Xiaodan Wang, Mengyue Niu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
Richard B. Lipton, Janette Contreras‐De Lama, Daniel Serrano, et al.
Neurology and Therapy (2023) Vol. 13, Iss. 1, pp. 69-83
Open Access | Times Cited: 5
Richard B. Lipton, Janette Contreras‐De Lama, Daniel Serrano, et al.
Neurology and Therapy (2023) Vol. 13, Iss. 1, pp. 69-83
Open Access | Times Cited: 5
New drugs targeting calcitonin gene-related peptide for the management of migraines
Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 233-240
Closed Access | Times Cited: 4
Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 233-240
Closed Access | Times Cited: 4
Non-Migraine Head Pain and Botulinum Toxin
Fatemeh Farham, Dilara Onan, Paolo Martelletti
Toxins (2024) Vol. 16, Iss. 10, pp. 431-431
Open Access | Times Cited: 1
Fatemeh Farham, Dilara Onan, Paolo Martelletti
Toxins (2024) Vol. 16, Iss. 10, pp. 431-431
Open Access | Times Cited: 1
Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand?
Lanfranco Pellesi
Frontiers in Pain Research (2023) Vol. 4
Open Access | Times Cited: 3
Lanfranco Pellesi
Frontiers in Pain Research (2023) Vol. 4
Open Access | Times Cited: 3
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
Andrew Blumenfeld, László Mechtler, Lisa Cook, et al.
Pain and Therapy (2024)
Open Access
Andrew Blumenfeld, László Mechtler, Lisa Cook, et al.
Pain and Therapy (2024)
Open Access
